TLDR Nilotinib can cause skin issues like red bumps and hair loss.
A 46-year-old man with chronic myelogenous leukemia (CML) developed keratosis pilaris atrophicans, characterized by red bumps and patchy hair loss, after starting nilotinib, a second-generation tyrosine kinase inhibitor. This case highlighted that cutaneous reactions, including pruritus, rash, dry skin, and alopecia, were common non-hematologic adverse effects of nilotinib. The patient's skin became dry and rough, with follicular accentuation and thinning of the eyebrows. It was important to distinguish these reactions from more severe drug hypersensitivity eruptions and to classify them based on morphology for better management.
December 2023 in “Journal of clinical medicine” Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
25 citations
,
November 2013 in “Journal of the American Academy of Dermatology” Many patients on new leukemia drugs had mild to moderate skin reactions.
32 citations
,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
42 citations
,
April 2012 in “Seminars in Oncology” Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
